SIG – FY sales EUR 1.35bn / EBITDA 203m / EBIT 90m / net profit 66m Outlook: 2007 EBIT and net income increasing, says outlook only valid if company stays independent, profit advances by 53% on sales growth and cost-cutting (BB).

Von Roll – FY net CHF 23.5m (vs cons 20m) / sales 532m (vs 537m) / EBIT 27.3m (vs cons 34m) Outlook: set mid-term sales growth target of 8% per year (BB).

CharlesVögele – FY sales CHF 1.32bn (-2% from FY’05) / EBITDA 143m / net profit 55m > post one-off goodwill impairment of CHF 74m: net loss CHF 20m > this was communicated on February 1st in an ad-hoc release Outlook: confirms full-year loss on write-off of Dutch Goodwill (BB).

BKW – FY revenues CHF 2.373bn (vs cons 2.221bn) / EBITDA 604m (vs cons 623m) / net profit 332m (vs cons 337m) Outlook: raises dividend from CHF 2.50 to CHF 2.70 (BB).

Roche Diagnostics announced that the US FDA has accepted for review its applications for 2 human papilloma-virus test (HPV).

Novartis – company gets US approval for Tekturna (Hypertension) – Novartis holds its AGM today(BB).

ABB selling loss-making division: sells German Gebäudetechnik division to WISAG Group for an undisclosed sum (turnover USD 305) and ACON Investment acquires ABB’s power line components business in Americas (terms not disclosed either) (BB).

Kaba – UBS cut price target from CHF 430 to CHF 400, rating buy (UBS research update)